
|Videos|September 8, 2017
Toxicities Associated With Rucaparib for the Treatment of Ovarian Cancer
Author(s)Jonathan Ledermann, MD
Jonathan Ledermann, MD, professor of medical oncology in the University College London Cancer Institute and director of Cancer Research UK and UCL Cancer Trials Centre, discusses the toxicities associated with rucaparib (Rubraca) for the treatment of ovarian cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















